Zenara Gets Nod to Manufacture, Sell Pfizer’s Paxlovid

Hyderabad-based Zenara Pharma on Thursday said it has received approval from India’s drug regulator to manufacture and sell the generic version of ‘s antiviral drug Paxlovid, which is indicated for the treatment of mild-to-moderate Covid-19 in adults.

The company said Nirmatrelvir and Ritonavir tablets will soon be available in a combi-pack, sold under the brand name Paxzen, as a treatment option for patients with mild to moderate symptoms of Covid-19. While the price of medicine is yet to be decided, it will be manufactured at Zenara’s USFDA-approved state-of-the-art facility in Hyderabad.

The approval has been granted under the emergency authorisation route. Multiple drug companies based in India have got the sub-licence from Medicines Patent Pool for the drug. Zenara is not a sub-licensee though.

(With inputs from health)